Factor Xa Inhibitors in the Control of Thrombogenesis

J. Fareed; Jeanine M. Walenga; Debra A. Hoppensteadt; Brigitte Kaiser; W. Jeske

doi:10.1055/s-0038-1660378

Hämostaseologie, Table of Contents

Hamostaseologie 1999; 19(01): 55-62
DOI: 10.1055/s-0038-1660378

Übersichtsarbeiten/Review Article

Schattauer GmbH

Factor Xa Inhibitors in the Control of Thrombogenesis

J. Fareed

¹Departments of Pathology and Pharmacology and Cardiovascular Institute, Loyola University Chicago, Maywood, Illinois and Center for Vascular Biology and Medicine, Friedrich Schiller University Jena, Erfurt, Germany

,

Jeanine M. Walenga

¹Departments of Pathology and Pharmacology and Cardiovascular Institute, Loyola University Chicago, Maywood, Illinois and Center for Vascular Biology and Medicine, Friedrich Schiller University Jena, Erfurt, Germany

,

Debra A. Hoppensteadt

¹Departments of Pathology and Pharmacology and Cardiovascular Institute, Loyola University Chicago, Maywood, Illinois and Center for Vascular Biology and Medicine, Friedrich Schiller University Jena, Erfurt, Germany

,

Brigitte Kaiser

¹Departments of Pathology and Pharmacology and Cardiovascular Institute, Loyola University Chicago, Maywood, Illinois and Center for Vascular Biology and Medicine, Friedrich Schiller University Jena, Erfurt, Germany

,

W. Jeske

¹Departments of Pathology and Pharmacology and Cardiovascular Institute, Loyola University Chicago, Maywood, Illinois and Center for Vascular Biology and Medicine, Friedrich Schiller University Jena, Erfurt, Germany

› Author Affiliations

Abstract

Summary

It is now well recognized that drugs with sole anti-Xa activity are capable of producing antithrombotic effects. The basic and clinical studies with pentasaccharide have validated this hypothesis. Synthetic heparin pentasaccharide is currently undergoing clinical trials in the prophylaxis of DVT in orthopedic surgery. While the naturally occuring direct anti-Xa agents such as antistatin, TAP and Yagin are potent anti-Xa agents their clinical development is delayed due to several unresolved developmental issues. On the other hand, several peptidomi-metic agents also demonstrate varying degrees of oral and subcutaneous bioavailability. One of these agents namely the DX 9065a is in clinical trials at this time. The factor Xa inhibitors exhibit a higher margin of safety in contrast to the antithrombin agents, however, their anticoagulant effects are somewhat weaker than the antithrombin agents. Thus, these agents may prove to be very useful in the prophylactic management of both the thrombotic and cardiovascular disorders. However, their use as an anticoagulant may not be very practical. These agents can be given as adjunct agents with hirudin and related antithrombin agents. These agents may also be of value in the outpatient management of thrombotic disorders. These agents may also be of value as an adjunct to various other antithrombotic drugs. Additional adjunct uses as with the antithrombin drugs, GP llb/llla inhibitors, thrombolytic agents and TFPI may increase the therapeutic index of many of these agents. It should be emphasized that each of these individual anti-Xa agents represent distinct drugs which require individual specific dosage optimization.

Keywords

Factor Xa - Xa inhibitor - thrombogenesis

Full Text

References

References
1 Samama MM, Walenga JM, Kaiser B, Fareed J. Specific factor Xa inhibitors. In Cardiovascular Thrombosis: Thrombocardiology. Eds. Verstraete M, Fuster V, Topol E. Brussels, Belgium: Lippincott-Raven; 1997: 173-88.
2 Weitz JI, Hirsh J. New antithrombotic agents. Chest 1998; 114: 715S-27S.
3 Vlasuk GP. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost 1993; 70: 212-6.
4 Tuszyuski G, Gasic TB, Gasic GJ. Isolation and characterization of antistatin. J Biol Chem 1987; 262: 9718-23.
5 Herbert JM, Bernât A, Dol F. et al. DX-9065a, a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. J Pharmacol Exper Ther 1997; 276: 1030-8.
6 Taniuchi Y, Sakai Y, Hisamichi N. et al. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb Haemost 1998; 79: 543-8.
7 Dunwiddie C, Thornberry NA, Bull HG. et al. Antistatin: a leech-derived inhibitor of factor Xa: kinetic analysis of enzyme inhibition and identification of the reactive site. J Biol Chem 1989; 264: 16694-9.
8 Hauptmann J, Kaiser B, Nowak G, Stürzebecher J, Markwardt F. Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors. Thromb Haemost 1990; 63: 220-3.
9 Kaiser B, Hauptmann J. Factor Xa inhibitors as novel antithrombotic agents: Facts and perspectives. Cardiovascular Drug Reviews 1994; 12: 225-36.
10 Kaiser B. Factor Xa versus factor Ha inhibitors. Clin Appi Thrombosis/Hemostasis 1997; 3 (01) 16-24.
11 Broze Jr GJ. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-3.
12 Walenga JM, Jeske WP, Bara L, Samama MM, Fareed J. State-of-the-art article. Biochemical and pharmacologic rationale for the development of a heparin pentasaccharide. Thromb Res 1997; 86: 1-36.
13 Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, and Gatti G. Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Acta 1983; 116: 492-9.
14 Sinay P, Jaquinet JE, Petitou M. et al. Total synthesis of a heparin pentasaccharide fragment having high affinity for antithrombin III. Carbohydr Res 1984; 132: C5-C9.
15 Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 1987; 46: 187-98.
16 Hobbelen PMJ, van Dinther TG, Vogel GMT, van Boeckel CAA, Moelker HCT, Meuleman DG. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb Haemost 1990; 63: 265-70.
17 Nagahara T, Katakurs S, Yokoyama T. et al. Design, synthesis and biological activities of orally active coagulation factor Xa inhibitors. Eur J Med Chem 1995; 30 Suppl 140S-143S.
18 Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M. DX 9065a, a new synthetic. Potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994; 71: 314-9.
19 Herbert JM, Heravlet JP, Bernat A, Van Amsterdam RG, Lormeau JC, Petitou M, Van Bouckel C, Hoffmann P, Newleman G. Biochemical and pharmacologic properties of sanorg 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91: 4197-205.
20 Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993; 91: 1877-83.
21 Meddahi S, Bara L, Uzan A, Samama MM. Pharmacologic modulation of human clots associated thrombin and prothrombinase activities by a direct anti Xa drug, r-hirudin and low molecular weight heparin. Haemostasis 1996; 26 (Suppl. 03) 578.
22 Ko FN, Yang YC, Huang SC, Ou JT. Coagulation factor Xa stimulates platelet-derived growth factor release and mitogenesis in cultured vascular smooth muscle cells of rat. J Clin Invest 1996; 98: 1493-501.
23 McNamara CA, Sarembock IJ, Bachhuber BG. et al. Thrombin and vascular smooth muscle cell proliferation: Implications for atherosclerosis and restenosis. Semin Thromb Hemost 1996; 22: 139-44.
24 Benzakour O, Kanthou C. Cellular and molecular events in atherogenesis: Basis for pharmacological and gene therapy approaches to restenosis. Cell Pharmacol 1996; 3: 7-22.
25 Kanthou C, Benzakour O. Cellular effects of thrombin and their signaling pathways. Cell Pharmacol 1995; 2: 293-302.
26 Ragosta M, Gimple LW, Gertz D. et al. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1994; 89: 1262-71.
27 Schwartz RS, Holder DJ, Holmes Jr DR, Veinot JP, Camrud AR, Jorgenson MA, Johnson RG. Neointimal thickening after severe coronary artery injury is limited by short-term administration of a factor Xa inhibitor. Results in a porcine model. Circulation 1996; 93: 1542-8.
28 Gasic GP, Arenas CP, Gasic TB, Gasic GJ. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA 1992; 89: 2317-20.
29 Elalamy I, Lecrubier C, Potevin F. et al. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin dependent factor of twenty-five patients with heparin associated thrombocytopenia. Thromb Haemost 1995; 74: 1384-5.
30 McKenzie CR, Abendschein DR, Eisenberg PR. Sustanained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. Arterioscler Thromb Vase Biol 1996; 16: 1285-91.